The KRAS-variant is one of the first discovered members of a new class of genetic markers that predict increased cancer risk and unique treatment response to cancer therapy. The biology of the KRAS-variant affords great promise for both preventing and curing cancer in individuals with this inherited mutation.



Currently, there are no biomarkers used before radiation therapy treatment to identify patients who have altered sensitivity to radiation therapy.  This treatment is used in over 67% of cancer patients.  MiraDx is developing a panel of such biomarkers, using extensive well-validated patient cohorts.  In addition, MiraDx is developing a program to confirm a diagnosis of  Ataxia Telangiectasia for children.


The KRAS-variant and Estrogen Management

As shown in numerous independent studies, women with the KRAS-variant are at an increased risk of developing breast and ovarian cancer, non-small cell lung cancer, and multiple primary breast cancer.  For studies about the best cancer prevention strategies for women with the KRAS-variant, please visit our sister non-profit, MiraKind.

New data now indicates that changing estrogen levels and estrogen withdrawal can be triggers for cancer in women with the KRAS-variant.  Knowing a woman’s KRAS-variant status is an additional piece of information to help direct decisions for estrogen management as well as screening for this population.

Personalized Medicine

The KRAS-variant has been shown to significantly predict sensitivity and resistant to cancer medicines for cancer patients.  This information can subgroup patients into responders or non-responders to therapies being used today as standard of care.  Currently work is ongoing to develop the best medicines to treat cancer patients with the KRAS-variant.



The Little-Known Genetic Mutation Behind Many Aggressive Cancers

Despite the dangers of the KRAS-variant mutation, few doctors have heard of it. But one researcher is trying to change that.

Read more

Are you interested in ongoing studies about the KRAS-variant?

Visit our sister non-profit Mirakind, and register for their newsletter to receive updates.